Advisory Services Network LLC Purchases 2,605 Shares of Gilead Sciences Inc. (GILD)
Advisory Services Network LLC boosted its stake in shares of Gilead Sciences Inc. (NASDAQ:GILD) by 7.5% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 37,128 shares of the biopharmaceutical company’s stock after buying an additional 2,605 shares during the period. Gilead Sciences makes up approximately 0.6% of Advisory Services Network LLC’s portfolio, making the stock its 28th largest position. Advisory Services Network LLC’s holdings in Gilead Sciences were worth $2,938,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Trust Co. of Oklahoma increased its stake in Gilead Sciences by 10.1% in the third quarter. Trust Co. of Oklahoma now owns 6,467 shares of the biopharmaceutical company’s stock worth $512,000 after buying an additional 593 shares in the last quarter. Lawson Kroeker Investment Management Inc. NE increased its stake in Gilead Sciences by 23.9% in the third quarter. Lawson Kroeker Investment Management Inc. NE now owns 129,329 shares of the biopharmaceutical company’s stock worth $10,233,000 after buying an additional 24,975 shares in the last quarter. Founders Financial Securities LLC purchased a new stake in Gilead Sciences during the third quarter worth $845,000. F&V Capital Management LLC increased its stake in Gilead Sciences by 3.7% in the third quarter. F&V Capital Management LLC now owns 78,410 shares of the biopharmaceutical company’s stock worth $6,204,000 after buying an additional 2,775 shares in the last quarter. Finally, Monarch Capital Management Inc. increased its stake in Gilead Sciences by 102.1% in the third quarter. Monarch Capital Management Inc. now owns 24,065 shares of the biopharmaceutical company’s stock worth $1,904,000 after buying an additional 12,160 shares in the last quarter. 73.59% of the stock is owned by institutional investors.
Gilead Sciences Inc. (NASDAQ:GILD) traded down 1.19% during trading on Monday, hitting $74.54. The stock had a trading volume of 9,338,882 shares. The stock has a market cap of $98.20 billion, a price-to-earnings ratio of 6.89 and a beta of 1.25. Gilead Sciences Inc. has a 12 month low of $71.39 and a 12 month high of $107.38. The stock has a 50 day moving average price of $74.54 and a 200-day moving average price of $80.07.
Gilead Sciences (NASDAQ:GILD) last released its earnings results on Tuesday, November 1st. The biopharmaceutical company reported $2.75 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.87 by $0.12. Gilead Sciences had a return on equity of 100.57% and a net margin of 47.74%. The business had revenue of $7.40 billion for the quarter, compared to analysts’ expectations of $7.47 billion. During the same quarter in the prior year, the business posted $3.22 EPS. The business’s revenue for the quarter was down 9.6% compared to the same quarter last year. On average, equities analysts predict that Gilead Sciences Inc. will post $11.47 EPS for the current year.
The company also recently declared a quarterly dividend, which will be paid on Thursday, December 29th. Investors of record on Thursday, December 15th will be paid a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a yield of 2.53%. The ex-dividend date of this dividend is Tuesday, December 13th. Gilead Sciences’s payout ratio is presently 17.44%.
A number of research firms have issued reports on GILD. Royal Bank Of Canada increased their price target on Gilead Sciences from $95.00 to $105.00 and gave the stock an “outperform” rating in a report on Monday, October 3rd. Bank of America Corp. restated a “neutral” rating and set a $100.00 price target on shares of Gilead Sciences in a report on Sunday, September 25th. Stifel Nicolaus began coverage on Gilead Sciences in a report on Monday, November 14th. They set a “buy” rating and a $100.00 price target on the stock. They noted that the move was a valuation call. Leerink Swann set a $112.00 price target on Gilead Sciences and gave the stock a “buy” rating in a report on Thursday, September 22nd. Finally, Mizuho began coverage on Gilead Sciences in a report on Monday, November 7th. They set a “buy” rating and a $88.00 price target on the stock. Ten equities research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and two have issued a strong buy rating to the company. Gilead Sciences presently has an average rating of “Buy” and a consensus price target of $97.90.
In related news, EVP Gregg H. Alton sold 5,000 shares of the stock in a transaction that occurred on Thursday, September 22nd. The stock was sold at an average price of $81.84, for a total transaction of $409,200.00. Following the completion of the transaction, the executive vice president now directly owns 132,964 shares of the company’s stock, valued at $10,881,773.76. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider John C. Martin sold 100,000 shares of the stock in a transaction that occurred on Thursday, September 1st. The shares were sold at an average price of $77.48, for a total value of $7,748,000.00. Following the transaction, the insider now directly owns 3,287,810 shares of the company’s stock, valued at $254,739,518.80. The disclosure for this sale can be found here. Corporate insiders own 1.40% of the company’s stock.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.
Receive News & Stock Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related stocks with our FREE daily email newsletter.